Taking stock of the drug industry, from the lab to the medicine chestJune 26, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Mario Tama/Getty Images STAT+ | STAT-Harris Poll: Nearly half of U.S. adults would spend $100 a month for Ozempic, other weight loss drugs STAT and The Harris Poll asked U.S. adults about their interest in new weight-loss drugs like Ozempic and their thoughts on pricing. By Ed Silverman and Elaine Chen STAT+ | In setback, Pfizer abandons one weight loss pill and bets on another The move by the drug giant to abandon the once-daily pill, lotiglipron, is seen as a setback by investors. By Matthew Herper STAT+ | Shareholders elect director's romantic partner to Biogen's board Susan Langer, the romantic partner of departing director Alex Denner, will join the eight-member board for a one-year term. By Damian Garde and Adam Feuerstein Kristoffer Tripplaar/AP STAT+ | Lilly's obesity pill cuts 15% of weight at highest dose in mid-stage trial A potential competitor to injectables like Mounjaro had similar side effects and would be as convenient as a daily pill. By Elaine Chen STAT+ | UnitedHealth wins $3.3 billion takeover of home health giant Amedisys Amedisys and UnitedHealth Group's Optum agreed to a deal Monday in which UnitedHealth will pay $3.3 billion total for Amedisys. By Bob Herman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments